Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a β-adrenergic receptor mechanism and decreased TNF-α gene expression

Journal of Immunology

Volumn 163, Issue 5, 1999, Pages 2492-2499

  Kalinichenko, Vladimir V ^a   Mokyr, Margalit B ^a   Graf Jr , Lloyd H ^a   Cohen, Rhonna L ^a   Chambers, Donald A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYCLIC AMP; MELPHALAN; MESSENGER RNA; MITOMYCIN C; NORADRENALIN; PROPRANOLOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTRACELLULAR FLUID; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MACROPHAGES; MELPHALAN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NOREPINEPHRINE; PLASMACYTOMA; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA; RNA, MESSENGER; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033198132     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chambers, D. A., R. L. Cohen, and R. L. Perlman. 1993. Neuroimmune modulation: signal transduction and catecholamines. Neurochem. Int. 22:95.
2. Felten, D. L., S. Y. Felten, S. L. Carlson, J. A. Olschowka, and S. Livnat. 1985. Noradrenergic and peptidergic innervation of lymphoid tissue. J. Immunol. 135: 755.
3. Felten, D. L., S. Y. Felten, D. L. Bellinger, S. L. Carlson, K. D. Ackerman, K. S. Madden, J. A. Olschowka, and S. Livnat. 1987. Noradrenergic sympathetic neural interactions with the immune system: structure and function. Immunol. Rev. 100:225.
4. Madden, K. S., and D. L. Felten. 1995. Experimental basis for neural-immune interactions. Physiol. Rev. 75:77.
5. Cook-Mills, J. M., R. L. Cohen, R. L. Perlman, and D. A. Chambers. 1995. Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology 85:544.
6. Sekut, L., B. R. Champion, K. Page, J. A. Menius, Jr., and K. M. Connolly. 1995. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin. Exp. Immunol. 99:461.
7. Sanders, V. M., R. A. Baker, D. S. Ramer-Quinn, D. J. Kasprowicz, B. A. Fuchs, and N. E. Street. 1997. Differential expression of the β-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J. Immunol. 158:4200.
8. Bartik, M. M., W. H. Brooks, and T. L. Roszman. 1993. Modulation of T cell proliferation by stimulation of the β-adrenergic receptor: lack of correlation between inhibition of T cell proliferation and cAMP accumulation. Cell. Immunol. 148:408.
9. Hadden, J. W., E. M. Hadden, and E. Middleton, Jr. 1970. Lymphocyte blast transformation. I. Demonstration of adrenergic receptors in human peripheral lymphocytes. Cell. Immunol. 1:583.
10. Feldman, R. D., G. W. Hunninghake, and W. L. McArdle. 1987. β-adrenergic-receptor-mediated suppression of interleukin 2 receptors in human lymphocytes. J. Immunol. 139:3355.
11. Guirao, X., A. Kumar, J. Katz, M. Smith, E. Lin, C. Keogh, S. E. Calvano, and S. F. Lowry. 1997. Catecholamines increase monocyte TNF receptors and inhibit TNF through β2-adrenoreceptor activation. Am. J. Physiol. 273:E1203.
12. Frohman, E. M., B. Vayuvegula, S. Gupta, and S. van den Noort. 1988. Norepinephrine inhibits γ-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via β-2-adrenergic signal transduction mechanisms. Proc. Natl. Acad. Sci. USA 85:1292.
13. Killeen, N. 1997. T-cell regulation: Thy-1-hiding in full view. Curr. Biol. 7:774.
14. Wajeman-Chao, S. A., S. A. Lancaster, L. H. Graf, Jr., and D. A. Chambers. 1998. Mechanism of catecholamine-mediated destabilization of messenger RNA encoding Thy-1 protein in T-lineage cells. J. Immunol. 161:4825.
15. Hatfield, S. M., B. H. Petersen, and J. A. DiMicco. 1986. β-adrenoreceptor modulation of the generation of murine cytotoxic T lymphocytes in vitro. J. Pharmacol. Exp. Ther. 239:460.
16. Cook-Mills, J. M., M. B. Mokyr, R. L. Cohen, R. L. Perlman, and D. A. Chambers. 1995. Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma. Cancer Immunol. Immunother. 40:79.
17. Gorelik, L., M. Rubin, A. Prokhorova, and M. B. Mokyr. 1995. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. J. Immunol. 154:3941.
18. Cohen, R. L., V. V. Kalinichenko, M. B. Mokyr, L. H. Graf, Jr., and D. A. Chambers. 1997. Norepinephrine inhibition of anti-tumor cytotoxicity can be mediated through the β adrenergic receptor. FASEB J. 11:1250.
19. Gorelik, L., and M. B. Mokyr. 1995. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s. c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome. Cancer Immunol. Immunother. 41:363.
20. + T cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 49:4597.
21. Mokyr, M. B., D. P. Braun, D. Usher, H. Reiter, and S. Dray. 1978. The development of in vitro and in vivo antitumor cytotoxicity in noncytotoxic tumor bearer spleen cells "educated" in vitro with MOPC-315 tumor cells. Cancer Immunol. Immunother. 4:143.
22. Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15:101.
23. + T cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res. 50:7641.
24. Gorelik, L., Y. Bar-Dagan, and M. B. Mokyr. 1996. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J. Immunol. 156:4298.
25. Weiskirch, L. M., and M. B. Mokyr. 1992. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated Balb/c mice bearing a large MOPC-315 tumor. Int. J. Cancer. 51:84.
26. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:411.
27. Siegel, J. P. 1988. Effects of interferon-γ on the activation of human lymphocytes. Cell. Immunol. 111:461.
28. Simon, M. M., U. Hochgeschwender, U. Brugger, and S. Landolfo. 1986. Monoclonal antibodies to interferon-gamma inhibit interleukin 2-dependent induction of growth and maturation in lectin/antigen-reactive cytolytic T lymphocyte precursors. J. Immunol. 136:2755.